Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Aug;5(4):e00333.
doi: 10.1002/prp2.333.

In vitro pharmacological characterization of a novel unbiased NOP receptor-selective nonpeptide agonist AT-403

Federica Ferrari  1 , Davide Malfacini  1 , Blair V Journigan  2 , Mark F Bird  3 , Claudio Trapella  4 , Remo Guerrini  4 , David G Lambert  3 , Girolamo Calo'  1 , Nurulain T Zaveri  2
Affiliations

In vitro pharmacological characterization of a novel unbiased NOP receptor-selective nonpeptide agonist AT-403

Federica Ferrari et al. Pharmacol Res Perspect. 2017 Aug.

Abstract

Nociceptin/orphanin FQ (N/OFQ) regulates several biological functions via selective activation of the N/OFQ receptor (NOP), a member of the opioid receptor family. We recently identified a new high affinity and highly selective NOP agonist AT-403. In this study, we characterized the functional profile of AT-403 and compared it to other known nonpeptide NOP agonists Ro 65-6570, Ro 2q, SCH-221510, MCOPPB, AT-202 and SCH-486757, using the following assays: GTPγ[35 S] stimulated binding, calcium mobilization assay in cells-expressing human NOP or classical opioid receptors and chimeric G proteins, bioluminescence resonance energy transfer (BRET) based assay for studying NOP receptor interaction with G protein and arrestin, and the electrically stimulated mouse vas deferens bioassay. All compounds behaved as NOP full agonists consistently showing the following rank order of potency MCOPPB > AT-403 > Ro 65-6570 = Ro 2q > SCH-221510 > AT-202 > SCH-486757. AT-403 and MCOPPB displayed the highest NOP selectivity both at human and murine receptors. Interestingly, while all the other nonpeptide NOP agonists displayed bias toward G protein-mediated signaling in the BRET assay, AT-403, similar to the natural ligand N/OFQ, behaved as an unbiased agonist, activating G-protein-mediated function as well as arrestin recruitment. AT-403 may be a useful nonpeptide tool compound to study the pharmacology of NOP activation in disease states.

Keywords: BRET arrestin assay; GPCR signaling bias; NOP receptor; functional selectivity; ligand bias; nonpeptide NOP agonists.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Chemical structures of the AT‐403 and other non‐peptide NOP agonists characterized in the present study.
Figure 2
Figure 2
GTPγ[35S]‐binding experiments. Concentration response curves to N/OFQ, Ro 65‐6570, Ro 2q, SCH‐221510 and MCOPPB (panel A), and to N/OFQ, AT‐403, AT‐202 and SCH‐486757 (panel B) in membranes of CHONOP cells. Data are the mean ± SEM of 6 separate experiments.
Figure 3
Figure 3
Calcium mobilization assay performed in Chinese Hamster Ovary cells expressing the NOP receptor and the chimeric Gα qi5 protein. Concentration response curves to N/OFQ, Ro 65‐6570, Ro 2q, SCH‐221510 and MCOPPB (panel A) and to N/OFQ, AT‐403, AT‐202 and SCH‐486757 (panel B). Data are expressed as mean ± SEM. of at least 4 separate experiments made in duplicate.
Figure 4
Figure 4
Calcium mobilization assay performed in Chinese Hamster Ovary cells expressing the NOP receptor and the chimeric Gα qi5 protein. Concentration response curves to N/OFQ (panel A), Ro 65‐6570 (panel B), Ro 2q (panel C), SCH‐221510 (panel D) and MCOPPB (panel E) in absence (control) and in presence of SB‐612111 100 nmol/L. Data are expressed as mean ± SEM. of at least 4 separate experiments made in duplicate.
Figure 5
Figure 5
Calcium mobilization assay performed in Chinese Hamster Ovary cells expressing the NOP receptor and the chimeric Gα qi5 protein. Concentration response curves to N/OFQ (panel A), AT‐403 (panel B), AT‐202 (panel C) and SCH‐486757 (panel D) in absence (control) and in presence of SB‐612111 100 nmol/L. Data are expressed as mean ± SEM. of at least 4 separate experiments made in duplicate.
Figure 6
Figure 6
Calcium mobilization assay performed in Chinese Hamster Ovary cells expressing opioid receptors and chimeric G proteins. Concentration response curves to opioid receptor standard agonists and to NOP receptor agonists in cells expressing the mu (panels A and B), the kappa (panels C and D), and delta (panels E and F) opioid receptors. Data are expressed as mean ± SEM of at least 4 separate experiments made in duplicate.
Figure 7
Figure 7
Bioluminescence resonance energy transfer assay.Concentration response curve to N/OFQ and NOP agonists in promoting NOP/G protein interaction (panels A and B) and NOP/β‐arrestin 2 interaction (panels C and D). Data are the mean ± SEM of 5 separate experiments made in duplicate.
Figure 8
Figure 8
Mouse vas deferens bioassay. Concentration response curves to N/OFQ and to NOP agonists. Data are the mean ± SEM. of at least 5 experiments. *P < 0.05 versus N/OFQ (Student t test for paired samples).
Figure 9
Figure 9
Representative tracings of the concentration response curve to N/OFQ and Ro 65‐6570 in the electrically mouse vas deferens.
Figure 10
Figure 10
Mouse vas deferens bioassay. Concentration response curve to DPDPE (panel A), N/OFQ (panel B), Ro 65‐6570 (panel C), Ro 2q (panel D), SCH‐221510 (panel E), MCOPPB (panel F), AT‐202 (panel G) and AT‐403 (panel H) in tissues taken from NOP(+/+) and NOP(−/−) mice. Data are the mean ± SEM. of at least 5 experiments.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Asth L, Ruzza C, Malfacini D, Medeiros I, Guerrini R, Zaveri NT, et al. (2016). Beta‐arrestin 2 rather than G protein efficacy determines the anxiolytic‐versus antidepressant‐like effects of nociceptin/orphanin FQ receptor ligands. Neuropharmacology 105: 434–442. - PMC - PubMed
    1. Bertorelli R, Bastia E, Citterio F, Corradini L, Forlani A, Ongini E (2002). Lack of the nociceptin receptor does not affect acute or chronic nociception in mice. Peptides 23: 1589–1596. - PubMed
    1. Berzetei‐Gurske IP, Schwartz RW, Toll L (1996). Determination of activity for nociceptin in the mouse vas deferens. Eur J Pharmacol 302: R1–2. - PubMed
    1. Bird MF, Cerlesi MC, Brown M, Malfacini D, Vezzi V, Molinari P, et al. (2016). Characterisation of the Novel Mixed Mu‐NOP Peptide Ligand Dermorphin‐N/OFQ (DeNo). PLoS ONE 11: e0156897. - PMC - PubMed
    1. Calo G, Rizzi A, Bogoni G, Neugebauer V, Salvadori S, Guerrini R, et al. (1996). The mouse vas deferens: a pharmacological preparation sensitive to nociceptin. Eur J Pharmacol 311: R3–5. - PubMed